Samsung Bioepis Co., Ltd. ("Samsung Bioepis") today presented the long-term safety data of EPYSQLItm (eculizumab; SB12), a biosimilar to Soliris1, in paroxysmal nocturnal hemoglobinuria (PNH) at the ...

INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...

The aHUS therapy landscape is on the cusp of disruption-with emerging oral drugs and biosimilars reshaping market dynamics ...

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028. See more on ZLAB stock here.

mechanism of action, and critical attributes like C5 inhibition. Clinical studies in patients with PNH confirmed comparable efficacy, safety, and pharmacokinetics between the biosimilars and reference ...

There have been recent developments in the use of neuromuscular ultrasound and MRI to aid in diagnosing MMN and in further elucidation of its pathophysiological mechanisms ... (CB)* Negative peak ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

Patients with neurologic involvement had significantly higher odds of receiving eculizumab therapy than those without (odds ratio, 13.03; 95% CI, 4.40-38.75); 74.5% of patients in the eculizumab ...

Epilepsy is primarily treated symptomatically—that is, the majority of the available medications aim to suppress seizures ...

"This preliminary work opens exciting avenues for future research to clarify the underlying mechanisms and to develop new improved therapies focusing on increasing energy expenditure for long-term ...